NCT02321852

Influence of Triflusal on Cognitive Functions in Healthy Subjects

Randomized Placebo Controlled Phase II Cross Over Study on the Influence of Triflusal on Cognitive Functions in Healthy Participants

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 40 (actual)
• Sponsor: Prof. Dominique de Quervain, MD · Academic / Other
• Sex: All
• Age: 18 Years – 40 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to investigate the effects of the eNOS activating agent triflusal on episodic memory and cognitive functions in healthy participants.

Detailed description

Randomised, placebo controlled, double blind, cross-over design Primary study outcomes are: Performance in picturial and verbal memory tasks. Main secondary outcomes are: Performance in working memory and cognitive tasks and influence on mood, depression and anxiety and motivation. Once daily oral administration of placebo mannitol for 7 days in a cross-over trial with a washout period of at least 14 days between the two periods. Each participant will take triflusal as well as placebo

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Triflusal	Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
DRUG	Placebo	Once daily oral administration of placebo mannitol for 7 days

Timeline

• Start date: 2015-01-01
• Primary completion: 2015-11-01
• Completion: 2015-11-01
• First posted: 2014-12-22
• Last updated: 2015-11-10

Locations

1 site across 1 country: Switzerland